Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Lorigerlimab

Catalog No. T77072 Copy Product Info
🥰Excellent
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].

Lorigerlimab

Copy Product Info
🥰Excellent
Catalog No. T77072

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].

Lorigerlimab
Cas No. 2416595-46-3
Pack SizePriceUSA StockGlobal StockQuantity
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetPD-1/CTLA-4
Chemical Properties
Cas No.2416595-46-3
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Lorigerlimab | purchase Lorigerlimab | Lorigerlimab cost | order Lorigerlimab